Brand name to generic substitution of antiepileptic drugs does not lead to seizure‐related hospitalization: a population‐based case‐crossover study

There is still controversy on brand‐to‐generic (B‐G) antiepileptic drugs (AEDs) substitution.

[1]  S. Ramsey,et al.  Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy , 2011, Epilepsia.

[2]  K. Kaiboriboon,et al.  Defining incident cases of epilepsy in administrative data , 2013, Epilepsy Research.

[3]  Daniel M. Hartung,et al.  Generic Substitution of Lamotrigine Among Medicaid Patients with Diverse Indications , 2012, CNS Drugs.

[4]  Carolyn M. Brown,et al.  Factors Associated with Seizure Recurrence in Epilepsy Patients Treated with Antiepileptic Monotherapy: A Retrospective Observational Cohort Study using US Administrative Insurance Claims , 2014, CNS Drugs.

[5]  M. Bialer.  Generic Products of Antiepileptic Drugs (AEDs): Is It an Issue? , 2007, Epilepsia.

[6]  G. Barkley,et al.  Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy , 2007, Neurology.

[7]  L. Goldstein,et al.  Characteristics of people with epilepsy who attend emergency departments: Prospective study of metropolitan hospital attendees , 2012, Epilepsia.

[8]  M. Feely,et al.  Are there potential problems with generic substitution of antiepileptic drugs? A review of issues , 2006, Seizure.

[9]  Josemir W Sander,et al.  Antiepileptic drugs: generic versus branded treatments , 2007, The Lancet Neurology.

[10]  A. Biraben,et al.  Current approaches to the use of generic antiepileptic drugs , 2007, Epilepsy & Behavior.

[11]  A. Kesselheim,et al.  Seizure Outcomes Following the Use of Generic versus Brand-Name Antiepileptic Drugs , 2010, Drugs.

[12]  Marie-Odile Cordier,et al.  Application of ILP to Cardiac Arrhythmia Characterization for Chronicle Recognition , 2001, ILP.

[13]  Marius Thomas Lindauer,et al.  Potassco: The Potsdam Answer Set Solving Collection , 2011, AI Commun..

[14]  J. Avorn,et al.  Refilling and Switching of Antiepileptic Drugs and Seizure‐Related Events , 2010, Clinical pharmacology and therapeutics.

[15]  A. Kesselheim.  The backlash against bioequivalence and the interchangeability of brand-name and generic drugs , 2011, Canadian Medical Association Journal.

[16]  Tias Guns,et al.  Constraint-Based Sequence Mining Using Constraint Programming , 2015, CPAIOR.

[17]  Martin Gebser,et al.  Knowledge-Based Sequence Mining with ASP , 2016, IJCAI.

[18]  B. D. Toffol,et al.  Utilisation des médicaments génériques des anti-épileptiques en France : résultats d’une enquête auprès des neurologues et revue de la littérature , 2007 .

[19]  K. Rascati,et al.  Effects of Antiepileptic Drug Substitutions on Epileptic Events Requiring Acute Care , 2009, Pharmacotherapy.

[20]  S. Helmers,et al.  Generic antiepileptic drugs and associated medical resource utilization in the United States , 2010, Neurology.

[21]  Giuseppe Capovilla,et al.  Recommendations of the Italian League Against Epilepsy Working Group on Generic Products of Antiepileptic Drugs , 2006, Epilepsia.

[22]  Brien Smith,et al.  Case‐control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes , 2009, Epilepsia.

[23]  S. Sullivan,et al.  Association between antiepileptic drug switching and epilepsy-related events , 2009, Epilepsy & Behavior.

[24]  R. Benecke,et al.  Generic substitution of antiepileptic drugs — A survey of patients' perspectives in Germany and other German-speaking countries , 2013, Epilepsy & Behavior.

[25]  S. Sullivan,et al.  Bioequivalent antiepileptic drug switching and the risk of seizure-related events , 2013, Epilepsy Research.

[26]  F. Andermann,et al.  Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to Branded Compounds Compared with Other Drug Classes , 2007, Epilepsia.

[27]  L. Boylan.  CLINICAL CONSEQUENCES OF GENERIC SUBSTITUTION OF LAMOTRIGINE FOR PATIENTS WITH EPILEPSY , 2009, Neurology.

[28]  J. Barron,et al.  Acute epilepsy exacerbations in patients switched between A-rated anti-epileptic drugs , 2010, Current medical research and opinion.

[29]  N. Jetté,et al.  Development and validation of a case definition for epilepsy for use with administrative health data , 2012, Epilepsy Research.

[30]  M Maclure,et al.  Case–crossover and case–time–control designs as alternatives in pharmacoepidemiologic research , 1997, Pharmacoepidemiology and drug safety.

[31]  M. Maclure.  The case-crossover design: a method for studying transient effects on the risk of acute events. , 1991, American journal of epidemiology.

[32]  R. Gross,et al.  Generic substitution in the treatment of epilepsy: Patient and physician perceptions , 2008, Epilepsy & Behavior.

[33]  J. Avorn,et al.  A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.

[34]  P. Greenberg,et al.  The risks and costs of multiple-generic substitution of topiramate , 2009, Neurology.

[35]  B. Bégaud,et al.  Pharmacoepidemiological research using French reimbursement databases: yes we can! , 2010, Pharmacoepidemiology and drug safety.